drugset / Trial / NCT00495651

Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)

NCT00495651 ↗

RandomizedFactorialOpen-labelTreatment

Summary

The Temprano trial is based on the following assumptions: * ART initiation at CD4 counts \<800/mm3 could significantly reduce the probability of severe HIV-related morbidity or death in the medium term. * Tuberculosis and tuberculosis-related deaths are likely to represent a considerable proportion of morbidity and mortality among HIV-infected patients with high CD4 counts in sub-Saharan Africa. Therefore, 6-month Isoniazide Prophylaxis for Tuberculosis (IPT) and early ART could enhance each others efficacy.

Timeline

Start
2008-03
Primary completion
2015-01
Completion
2015-01

Outcome

Met primary endpoint

paper The risk of death or severe HIV-related illness was lower with early ART than with deferred ART PMID 26193126 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Antiretroviral medications Unknown — —
Subject Efavirenz Other / unclassified — —
Subject Isoniazid Small molecule 300 mg —
Subject Lopinavir Other / unclassified — —
Subject Ritonavir Other / unclassified — —
Subject Tenofovir Small molecule — —
Subject emtricitabine Other / unclassified — —